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Abstract
Mutations in MECP2 cause several neurological disorders of
which Rett syndrome (RTT) represents the best-defined condi-
tion. Although mainly working as a transcriptional repressor,
MeCP2 is a multifunctional protein revealing several activities,
the involvement of which in RTT remains obscure. Besides being
mainly localized in the nucleus, MeCP2 associates with the
centrosome, an organelle from which primary cilia originate.
Primary cilia function as “sensory antennae” protruding from
most cells, and a link between primary cilia and mental illness
has recently been reported. We herein demonstrate that MeCP2
deficiency affects ciliogenesis in cultured cells, including neurons
and RTT fibroblasts, and in the mouse brain. Consequently, the
cilium-related Sonic Hedgehog pathway, which is essential for
brain development and functioning, is impaired. Microtubule
instability participates in these phenotypes that can be rescued
by HDAC6 inhibition together with the recovery of RTT-related
neuronal defects. Our data indicate defects of primary cilium as
a novel pathogenic mechanism that by contributing to the clini-
cal features of RTT might impact on proper cerebellum/brain
development and functioning, thus providing a novel therapeutic
target.
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Introduction
The Methyl-CpG-binding Protein 2 (MECP2) gene, localized on the X
chromosome, codes for a multifunctional epigenetic regulator with a
prominent role in brain. Accordingly, MECP2 mutations are linked
to several neurological conditions characterized by cognitive impair-
ment and intellectual disability (Ezeonwuka & Rastegar, 2014). In
particular, loss-of-function mutations are mainly associated with
Rett (RTT) syndrome, a severe neurodevelopmental disease that
principally affects females (Amir et al, 1999; Chahrour & Zoghbi,
2007). Less frequently, MECP2 mutations cause autism, schizophre-
nia, mental retardation, Angelman-like syndrome in both genders
and neonatal encephalopathy in males (Ezeonwuka & Rastegar,
2014). In parallel, a non-physiological increase in MeCP2 expression
is responsible for the recently identified MECP2 duplication
syndrome, mainly affecting males (Ramocki et al, 2010). In accor-
dance with its ubiquitous expression, MECP2 has also been linked
to non-neurological diseases, such as lupus erythematosus, rheuma-
toid arthritis and cancer (Ezeonwuka & Rastegar, 2014).
Originally isolated as the first protein able to specifically bind
methylated cytosines, MeCP2 is generally described as an epigenetic
transcriptional regulator that represses transcription of methylated
DNA. This repressive activity is mainly mediated by the ability of
MeCP2 to recruit corepressor complexes able to modify chromatin
structure (Clouaire & Stancheva, 2008). In addition to its proposed
role in gene silencing and chromatin architecture, several other func-
tions have more recently been ascribed to MeCP2. Indeed, nowadays
MeCP2 appears as a multifunctional protein that manifests different
activities depending on its partners and post-translational modifi-
cations (Young et al, 2005; Chahrour et al, 2008; Ghosh et al, 2010;
Skene et al, 2010; Bedogni et al, 2014; Bellini et al, 2014).
Accordingly, we have recently demonstrated that MeCP2 is func-
tionally associated with centrosomes and, similarly to many
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centrosomal proteins, its deficiency causes aberrant spindle geome-
try, defects in cell proliferation, microtubule nucleation and
prolonged mitosis. This novel function reconciled previous data
regarding a role of MeCP2 in cell growth, cytoskeleton stability, and
axonal transport (Bergo et al, 2015). While in cycling cells, the
centrosome organizes the interphase microtubule network and the
mitotic spindle, in most quiescent or post-mitotic non-cycling cells,
it participates in the nucleation of primary cilia (Stearns, 2001). We
thus decided to investigate whether MeCP2 defects could play a role
also in primary cilium formation and functioning.
Primary cilium is a non-motile microtubule-based organelle that
grows from a centrosome-derived structure, termed the basal body,
and protrudes from the cell surface of almost every quiescent or dif-
ferentiated mammalian cell, including neurons (Guemez-Gamboa
et al, 2014). It consists of an axoneme, formed by a radial array of
nine doublet microtubules of polymerized a/b-tubulin heterodimers,
and the process of intraflagellar transport (IFT) is responsible for
building and maintaining cilium structure and function (van Reeu-
wijk et al, 2011; Pala et al, 2017; Youn & Han, 2018). Primary
cilium is a sensory organelle that receives and transduces many
extracellular signals, thereby influencing a wide variety of cellular
processes, such as proliferation, differentiation, migration, and
apical–basal polarity in cortical development and neuronal growth
(van Reeuwijk et al, 2011; Pala et al, 2017; Youn & Han, 2018; Park
et al, 2019). In accordance with its main function, several receptors
for signaling cascades, such as Sonic Hedgehog (Shh), PDGF,
mTOR, Wnt, Notch, planar cell polarity (PCP) and Hippo, accumu-
late in the membrane of primary cilium (Goetz & Anderson, 2010;
Pala et al, 2017; Wheway et al, 2018). The importance of this orga-
nelle in normal physiology is exemplified by a growing list of
genetic disorders, known as “ciliopathies”, caused by dysfunctional
ciliary assembly, anchoring and/or signaling, characterized by a
high variability in clinical presentation (Novarino et al, 2011; Ware
et al, 2011; Lee & Gleeson, 2014; Valente et al, 2014; Reiter &
Leroux, 2017). Interestingly, among the variety of clinical features,
some symptoms such as developmental delay, cognitive disabilities,
ataxia, tendency for obesity, bone loss and defects in respiration
rhythms are also manifested by RTT patients (Kyle et al, 2018).
Furthermore, a recent study has indicated that among 41 genes
connected to diverse neuropsychiatric disorders, 23 are involved in
primary cilium assembly and disassembly (Marley & von Zastrow,
2012).
Cilium assembly/disassembly depends on a great number of dif-
ferent factors that have to be optimally tuned in order to generate
cilia of the right size and length, thereby ensuring proper function-
ing (Keeling et al, 2016). Among these factors, acetylation of lysine
(K) 40 of a-tubulin is pivotal for maintaining primary cilium;
indeed, its HDAC6-dependent deacetylation leads to the disassembly
of the organelle (Forcioli-Conti et al, 2016). Importantly, MECP2-de-
ficient cells, including fibroblasts from RTT patients, are character-
ized by the upregulation of HDAC6 and, consequently, reduced
acetylation of polymerized a-tubulin and microtubule instability
(Dele´pine et al, 2013, 2016; Gold et al, 2015).
Considering all above, for the first time, we have investigated
and identified primary cilium dysfunctions in vitro in all tested cells,
including fibroblasts from RTT patients, and in vivo in Mecp2 null
and heterozygous brains, demonstrating a causal connection
between MeCP2 expression and ciliogenesis. Importantly, these
defects reflect, both in vitro and in vivo, a functional impairment of
the ciliary-related Shh signaling pathway. Stabilization of a-tubulin,
through a selective inhibition of HDAC6, can revert the observed
morphological and functional ciliary alterations, in concomitance
with a recovery of RTT-related phenotypes in Mecp2 null neurons.
Results
Primary cilium formation is facilitated by MeCP2
As mentioned above, we have recently demonstrated a molecular
and functional association between MeCP2 and the centrosome, the
cellular organelle that templates the assembly of primary cilium
(Bergo et al, 2015). Almost every quiescent or post-mitotic mamma-
lian cell presents a primary cilium; we thus investigated whether
MeCP2 deficiency affects the presence and/or length of the primary
cilium on the cell surface.
First, we compared wild-type (WT) and Mecp2 null mouse quies-
cent embryonic fibroblasts (MEFs). Ciliated cells were detected by
immunofluorescence staining for acetylated a-tubulin and ɣ-tubulin,
two microtubule proteins that are enriched, respectively, in the
axoneme and the basal body of the cilium, where they are critical
for maintaining its structure (Fig 1A). As shown in Fig 1B, the
percentage of ciliated cells was significantly decreased by 38%
compared to WT cells (**P < 0.01, Mann–Whitney test). Since
almost 53% of Mecp2 null cells showed a primary cilium, we
measured its length. Nascent or extended acetylated a-tubulin
emerging from the ɣ-tubulin-positive centriole was measured,
revealing that Mecp2 null MEFs show a statistically significant
reduction in cilium length (***P < 0.001, Student’s t-test; Fig 1C).
Similar results were obtained analyzing MEFs from a Mecp2Y120D/y
knock-in mouse mimicking a pathogenic human mutation
(*P < 0.05, Mann–Whitney test; Fig EV1; Gandaglia et al, 2018). To
support these data, we repeated the same analyses in hTERT-RPE-1
(immortalized retinal pigment epithelial) cells interfered with a
specific MeCP2-siRNA, reducing MeCP2 expression to less than half,
as revealed by Western blot (Fig 1E). Accordingly, immunofluores-
cence analysis proved that almost 40% of cells show a positive
MeCP2 signal (***P < 0.001, Student’s t-test; Fig 1F). Primary cilia
were stained and analyzed (Fig 1D). Quantitative analyses indicated
that the percentage of ciliated cells was significantly reduced
compared to control (***P < 0.001, Mann–Whitney test; Fig 1G)
and, when present, cilium length was significantly decreased in
silenced cells (***P < 0.001, Student’s t-test; Fig 1H). Since Rett
syndrome is a neurological disorder affecting both neurons and
astrocytes, we also analyzed ciliogenesis in these cells. Primary
neurons derived from WT or Mecp2 null embryonic cortices were
fixed at different maturation stages and cilium was detected by
immunostaining for adenylate cyclase type 3 (AC3), a protein
expressed in the primary cilium of neurons (Bishop et al, 2007;
Fig 1I). Indeed, it is well recognized that the antibody against acety-
lated a-tubulin, which is commonly used to mark the primary cilium
in several non-neuronal cell types, in neurons causes a diffuse stain-
ing throughout the cell body and neurites, thus preventing its use as
valid cilium marker (Berbari et al, 2013). The staining was
conducted at DIV3, DIV7 and DIV14. Results revealed an impair-
ment in the percentage of ciliated cells and in cilium length
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(*P < 0.05, two-way ANOVA followed by Bonferroni post hoc test),
indicating a defective ciliogenesis in Mecp2 null neurons compared
to controls, in front of a progressive increase of ciliogenesis in both
WT and null neurons along neuronal maturation (F (2, 584) = 44.06
for % ciliated cells; F (2, 551) = 30.68 for cilium length) (Fig 1J and
K). In a similar way, cortical astrocytes were analyzed by immunos-
taining cilia for acetylated a-tubulin and c-tubulin (Fig 1L–N) and a
significant reduction in both the percentage of ciliated cells and in
cilium length was demonstrated (*P < 0.05, Student’s t-test).
To confirm that MeCP2 expression is involved in the observed
phenotypes, we performed a rescue experiment on Mecp2 null
primary neurons (Fig 2). WT and Mecp2 null cortical neurons
were infected at DIV0 with lentiviruses expressing GFP or
MeCP2iresGFP, and the expression of MeCP2 was verified by
Western blot (Fig 2B). At DIV7, neuronal cilium was immunos-
tained for AC3 (Fig 2A) and the percentage of ciliated cells and
cilium length were determined only on GFP-positive cells. We con-
firmed the impairment in primary cilium formation in Mecp2 null
neurons and demonstrated a significant recovery of the phenotype
following MeCP2 expression (***P < 0.001, two-way ANOVA
followed by Bonferroni post hoc test) (Fig 2C). Similarly, MeCP2
transduction fully recovered cilium length in Mecp2 null neurons
(***P < 0.001; **P < 0.01, two-way ANOVA followed by Bonfer-
roni post hoc test) (Fig 2D).
Mecp2 deficiency affects the cilium-associated Sonic Hedgehog
(Shh) signaling pathway
Since our data demonstrate that MeCP2 deficiency is associated
with morphological alterations of the primary cilium, we proceeded
investigating ciliary functions. We focused our analysis on the Shh
cascade, because this signaling pathway is generally recognized as
the one that is mainly associated with primary cilia (Wheway et al,
2018). Shh activation can be detected by measuring the levels of
various components of its pathway along the primary cilium or in
a ciliary subdomain. In particular, the binding of the ligand Shh to
its receptor, protein patched homolog 1 (Ptch1), triggers the accu-
mulation of Smoothened (Smo) within the ciliary membrane with
the consequent activation of Gli transcription factors (Fig 3A). We
thus analyzed Smo localization in the primary cilium of starved
hTERT-RPE-1 cells silenced for MeCP2 and treated with SAG, a
Smo agonist able to activate the Shh pathway (Fig 3B). To assess
the percentage of Smo-positive cilia, cells were stained for Smo
and acetylated a-tubulin; the results demonstrated that MeCP2
depletion significantly impairs the ciliary accumulation of Smo
upon Shh stimulation (***P < 0.001, two-way ANOVA followed by
Bonferroni post hoc test). Similar results were obtained in Mecp2
null MEFs following SAG exposure and a significant difference
between cells was evident when the higher dose of SAG was used
(*P < 0.05, two-way ANOVA followed by Bonferroni post hoc test;
Fig 3C).
To further support a functional defect of the Shh signaling path-
way in Mecp2-defective cells, the protein and mRNA levels of the
downstream transcription factor Gli1 were measured in cultured
MEFs and neurons. Western blots from SAG-treated and untreated
cells proved that the lack of Mecp2 impairs Gli1 activation (Fig 3D
and E). Indeed, while a significant increase in Gli1 expression was
measured both in WT MEFs and in neurons (***P < 0.001, two-way
ANOVA followed by Bonferroni post hoc test), the activation of the
Shh pathway did not lead to a significant Gli1 induction in Mecp2
null cells. Accordingly, Gli1 levels were significantly reduced in
SAG-treated Mecp2 null cells with respect to WT (*P < 0.05;
**P < 0.01, two-way ANOVA followed by Bonferroni post hoc test).
By analyzing Gli1 mRNA, we confirmed the defective response to
SAG in both Mecp2 null cells, although cortical neurons exhibited a
trend that did not reach statistical significance (Fig 3F and G). Of
note, the low expression of Gli1 mRNA in basal conditions did not
permit quantitative analysis.
◀ Figure 1. MeCP2 deficiency affects primary cilium formation.A Representative immunofluorescence of primary cilium in WT or Mecp2 null MEF cells. Cells were starved for 48 h before staining with anti-c-tubulin (green) and
anti-acetylated a-tubulin (red) antibodies. Merge of all channels and DAPI staining (blue) is depicted for both genotypes. Scale bar 20 lm, and 10 lm in the
enlarged image. Arrows indicate not ciliated cells.
B, C Cilia were counted and analyzed with ImageJ to quantify the percentage of ciliated cells (n = 134 WT and n = 140 Mecp2 null cells) (B) and the cilium length
(n = 104 WT and n = 43 Mecp2 null cells) (C). The graphs show the average of three independent experiments (mean  SE, **P < 0.01, Mann–Whitney test;
***P < 0.001, Student’s t-test).
D Representative immunofluorescence of primary cilium in hTERT-RPE-1 cells silenced with MECP2 or control siRNAs. Cells were starved for 48 h before staining
with anti-c-tubulin (green) and anti-acetylated a-tubulin (red) antibodies. Scale bar 10 lm, and 5 lm in the enlarged image. Arrows indicate not ciliated cells.
E Representative Western blotting showing the MeCP2 expression in CTRL and silenced hTERT-RPE-1 cells, with respect to GAPDH, used as loading control.
F The percentage of MeCP2-positive cells was calculated by analyzing n = 1,000 CTRL and silenced hTERT-RPE-1 cells (mean  SE, ***P < 0.001, Student’s t-test).
G, H Cilia were counted and analyzed with ImageJ to quantify the percentage of ciliated cells (n = 191 CTRL and n = 197 siMeCP2 cells) (G) and the cilium length
(n = 50 CTRL and n = 50 siMeCP2 cells) (H). The graphs show the mean  SE of three independent experiments (***P < 0.001, Mann–Whitney test (G) or
Student’s t-test (H)).
I Representative immunofluorescence of primary cilium in WT and Mecp2 null primary cortical neurons at DIV7 and DIV14. Scale bar = 10 lm, and 5 lm in the
enlarged image. Arrows indicate not ciliated cells.
J, K Neurons were fixed at DIV3, DIV7, and DIV14, and primary cilium was detected by immunostaining with anti-AC3 antibody. Percentage of ciliated cells (J) and
cilium length (K) were analyzed. Histograms represent the average of three independent experiments, analyzing neurons derived from 3 different experiments
(n = 156 WT DIV3; n = 49 KO DIV3; n = 177 WT DIV7; n = 82 KO DIV7; n = 59 WT DIV14; and n = 37 KO DIV14) (mean  SE, **P < 0.01; ***P < 0.001, two-way
ANOVA followed by Bonferroni post hoc test).
L Primary cortical astrocytes were fixed at DIV15 and stained with anti-acetylated a-tubulin (red) and anti-ɣ-tubulin (green) antibodies. Scale bar = 20 lm, and
10 lm in the enlarged image. Arrow indicates not ciliated cell.
M, N Percentage of ciliated cells (M) and cilium length (N) were analyzed (n = 26 WT and n = 34 Mecp2 null astrocytes). Histograms represent the average of three
independent experiments (mean  SE, *P < 0.05, Student’s t-test).
Source data are available online for this figure.
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Mecp2 deficiency is associated with a significant shortening of
primary cilia in the cerebral cortex and cerebellum
Disruption of neuronal primary cilia can induce defects in neuronal
connectivity and reduce intellectual functions (Lee & Gleeson, 2014;
Reiter & Leroux, 2017). Thus, we investigated whether Mecp2 defi-
ciency could also affect ciliogenesis in vivo. Considering the involve-
ment of cerebral cortex in RTT, we initially focused on the Mecp2
null developing cortex (P14). As shown in Fig 4A–C, in knock-out
cortices, cilium length was significantly reduced compared to WT
controls (*P < 0.05, Mann–Whitney test). To identify the most
affected cortical layers, the analysis was conducted separately for
each layer; besides a significant genotype effect (F (1, 20) = 45.61,
P < 0.001), post hoc analysis indicated a significant reduction in
cilium length in layers 1, 2/3, and 4 (***P < 0.001; **P < 0.01;
*P < 0.05, two-way ANOVA followed by Bonferroni post hoc test;
Fig 4C).
Although primary cilium is present in most neurons, its role for
cerebral cortex development and functioning still remains debated;
on the contrary, the primary cilium and the associated Shh pathway
are recognized as master players for cerebellum development. In
particular, in the cerebellum, Shh activation starts at E17.5, peaks at
P5-P8, and then progressively declines (De Smaele et al, 2008; Vail-
lant & Monard, 2009). We thus analyzed cilium length in P7
A
B
C D
Figure 2. MeCP2 expression in null neurons rescues primary cilium defects.
A Representative immunofluorescence of Mecp2 null cortical neurons infected at DIV0 with lentiviruses expressing GFP or MeCP2iresGFP. Neurons were fixed at DIV7
and immunostained with anti-AC3 antibody to detect the primary cilium. GFP-positive cells represent infected cells. Scale bar = 20 lm, and 10 lm in the enlarged
image.
B Western blot comparing MeCP2 levels in Mecp2 null neurons infected with lentiviruses expressing GFP or MeCP2iresGFP with respect to WT neurons. Data are
normalized to total protein content, visualized by a TGX stain-free technology.
C, D MECP2 expression in null neurons induced a significant recovery of ciliogenesis. (C) The graph represents the percentage of ciliated cells, counting n = 50 WT and
n = 100 null cells of two different preparations (mean  SE, ***P < 0.001, two-way ANOVA followed by Bonferroni post hoc test). Statistical analysis reported a
significant interaction (F (1, 135) = 8.264), a significant genotype effect (F (1, 135) = 37.59), and a significant infection effect (F (1, 135) = 26.89). (D) The graph
represents the mean  SE of cilium length in WT and Mecp2 null neurons infected with GFP- or MeCP2iresGFP-expressing lentiviruses, counting n = 28 cells of
two different preparations (**P < 0.01; ***P < 0.001, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA reported a significant interaction
(F (1, 103) = 6.405), a significant genotype effect (F (1, 103) = 35), and a significant infection effect (F (1, 103) = 4.039).
Source data are available online for this figure.
ª 2020 The Authors EMBO Molecular Medicine e10270 | 2020 5 of 18
Angelisa Frasca et al EMBO Molecular Medicine
cerebella, including in the study both Mecp2 null and heterozygous
tissues and discriminating the external (EGL) and the internal (IGL)
granular layers (Fig 4D). In good accordance with the more mature
state, the WT IGL revealed a longer primary cilium than the WT
EGL, while the gender did not play any effect. Importantly, a
significant reduction of cilium length was measured in the two
layers of both Mecp2 null and heterozygous cerebella (**P < 0.01;
***P < 0.001, Mann–Whitney test), although the magnitude of the
effect was higher in knock-out tissues (Fig 4E and F). To support
the observed morphological defects, we analyzed Gli1 expression
A B
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Figure 3.
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in the Mecp2 null cerebellum, which manifests a more severe
phenotype. Our results indicated a significant reduction of both
Gli1 protein and mRNA (*P < 0.05, Student’s t-test; Fig 4G and H).
Gli1 deficiency was supported by a transcriptional reduction of its
direct targets, Cyclin D1 (*P < 0.05, Student’s t-test) and Cyclin
D2 (revealing only a trend of reduction) (Fig 4H; Kenney &
Rowitch, 2000).
Microtubule instability participates in the observed
ciliary defects
As already mentioned, ciliary assembly and elongation are nega-
tively influenced by microtubule instability, a defect that is
known to occur when MeCP2 is deficient (Dele´pine et al, 2013,
2016). Previously, we have demonstrated that MeCP2 depletion
affects the microtubule nucleation potential of the centrosome
(Bergo et al, 2015); accordingly, RTT patients’ fibroblasts are
characterized by defective microtubule polymerization and
increased HDAC6 levels (Gold et al, 2015). By deacetylating a-
tubulin, HDAC6 acts as a key driver of primary cilium disassem-
bly and has already been proposed as a possible therapeutic
target for ciliopathies (Yu et al, 2016).
Considering all above, we initially used tubacin, a potent, selec-
tive and cell-permeable HDAC6 inhibitor, to determine whether
microtubule stabilization might recover the observed ciliary pheno-
types. After starvation, WT and Mecp2 null MEFs were treated with
vehicle (DMSO) or tubacin (1 lM) for 48 h and then stained for
acetylated a-tubulin to detect cilia. As depicted in Fig 5A, tubacin
significantly restored the percentage of ciliated Mecp2 null MEFs
(*P < 0.05, two-way ANOVA followed by Bonferroni post hoc test)
and post hoc analysis confirmed the already-known ciliary defects in
Mecp2 null cells (*P < 0.05; **P < 0.01, two-way ANOVA followed
by Bonferroni post hoc test). Importantly, similar results were
obtained when Mecp2 null cortical neurons were treated with
tubacin (Fig 5B) (*P < 0.05; **P < 0.01, two-way ANOVA followed
by Bonferroni post hoc test).
To determine whether the observed morphological rescue could
be associated with a functional recovery, we investigated the Shh
pathway after tubacin treatment in MECP2-silenced hTERT-RPE-1
cells. In particular, we analyzed whether the drug could rescue Smo
translocation into the primary cilium upon Shh activation (Fig 5C
and D). Control or MECP2-silenced hTERT-RPE-1 cells were treated
with tubacin or DMSO, and then with SAG (200 nM). The analysis
of the percentage of Smo-positive cilia confirmed the defective
◀ Figure 3. Mecp2 deletion impairs Shh signaling pathway.A Schematic representation of the Shh pathway in the cilium.
B MECP2-silenced or control hTERT-RPE-1 cells were starved for 48 h before treatment with 200 and 500 nM SAG for 24 h. Cells were stained with anti-Smo and
anti-acetylated a-tubulin antibodies. The percentages of Smo-positive cilia were calculated. The graph shows the average of three independent experiments
(mean  SE, *** P < 0.001, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA demonstrated a significant silencing effect (F (1, 12) = 160,
P < 0.0001), a significant SAG treatment (F (2, 12) = 259.4, P < 0.0001), and a significant interaction (F (2, 12) = 36.85, P < 0.0001).
C WT or Mecp2 null MEF cells were treated with SAG (200 and 500 nM) for 24 h, and the percentages of Smo-positive cilia were calculated. The graph shows the
average of three independent experiments (mean  SE, *P < 0.05, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA indicated a significant
genotype effect (F (1, 12) = 11.22, P < 0.01) and a significant SAG treatment (F (2, 12) = 11.7, P < 0.0001).
D Gli1 protein levels were measured by Western blot in untreated (UT) and 100 nM SAG-treated WT and Mecp2 null MEF cells (n = 5/6). Representative bands of Gli1,
Mecp2, and a-tubulin are depicted above the histogram, which shows the mean  SE of the percentage of Gli1 expression levels, compared to the untreated WT
samples (**P < 0.01; ***P < 0.001, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA reported a significant interaction (F (1, 18) = 6.652,
P < 0.05), a significant genotype effect (F (1, 18) = 15.95, P < 0.001), and a significant treatment (F (1, 18) = 20.15, P < 0.001).
E Gli1 protein levels were measured by Western blot in WT and Mecp2 null neurons, following SAG treatment (200 and 400 nM). Representative bands of Gli1,
Mecp2, and a-tubulin are depicted above the histogram, which shows the mean  SE of the percentage of Gli1 expression levels, compared to the untreated WT
samples (*P < 0.05, ***P < 0.001, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA indicated a significant interaction (F (2, 20) = 3.788,
P < 0.05), a significant genotype effect (F (1, 20) = 4.362, P < 0.05), and a significant treatment (F (2, 20) = 13.5, P < 0.001).
F, G Gli1 mRNA expression levels upon SAG exposure in MEF cells (n = 7 WT and n = 9 null samples) (F; SAG 100 nM) and cortical neurons (n = 15 WT and n = 12 null
samples) (G; SAG 400 nM). The graphs show the mean  SE of the fold change derived from at least three independent experiments (mean  SE, **P < 0.01, two-
way ANOVA followed by Bonferroni post hoc test).
Source data are available online for this figure.
▸Figure 4. Primary cilia defects are present in the cortex and cerebellum of Mecp2 mutant brains.Primary cilium length was measured in the cortex of Mecp2 null mice and cerebellum of Mecp2 null and heterozygous mice.
A Representative immunostaining of Arl13b (red) and c-tubulin (green) in the P14 mouse cortical layers. Nuclei were stained with DAPI (blue). Scale bar = 10 lm.
B, C Average cilium length was measured in the cortex (mean  SE, n = 4 WT and n = 3 Mecp2 null) (B; *P < 0.05, Mann–Whitney test) and for each cortical layer
(C; ***P < 0.001; **P < 0.01; *P < 0.05, two-way ANOVA followed by Bonferroni post hoc test). In (C), cilium length is analyzed in separate cortical layers, while in
(B), the values indicate the average of cilium lengths for each layer.
D Representative immunostaining of Arl13b (green) in the internal (IGL) and external (EGL) granular layers of Mecp2 null (n = 3) and heterozygous (het) cerebella
(n = 3) at P7, and the corresponding WT (n = 3 males and n = 3 females). Nuclei were stained with DAPI (blue). Scale bar = 5 lm.
E, F Histograms show the mean  SE of cilium length (n = 3 male WT, n = 3 female WT, n = 3 Mecp2 null and Mecp2 het; **P < 0.01; ***P < 0.001, Mann–Whitney
test) in Mecp2 null (E) and heterozygous (F) mice, compared to the corresponding WT.
G Gli1 protein levels were measured by Western blot in WT and Mecp2 null cerebellum (n = 7 WT and n = 6 Mecp2 null). Representative bands of Gli1 and a-tubulin
are depicted beside the histogram, which shows the mean  SE of the percentage of Gli1 expression levels, compared to WT animals (*P < 0.05, Student’s t-test).
H The mRNA expression levels of Gli1 and its downstream genes (Cyclin D1 and D2) were analyzed in WT and Mecp2 null cerebella (n = 8 WT and n = 7 Mecp2 null).
The graph shows the fold change of transcripts compared to WT (mean  SE, *P < 0.05, Student’s t-test).
Source data are available online for this figure.
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activation of the Shh pathway in silenced cells that was rescued by
tubacin treatment (**P < 0.01, three-way ANOVA followed by
Tukey’s post hoc test).
To reinforce our results, we investigated whether in concomi-
tance with restored ciliogenesis, we could observe an amelioration
of neuronal alterations that are commonly detected in Mecp2 null
cells and that are relevant for Rett syndrome. WT and Mecp2 null
neurons were thus treated with tubacin or TC-S 7010, a specific inhi-
bitor of the centrosomal kinase Aurora A. In neurons, Aurora A acts
by phosphorylating and activating HDAC6 at the basal body, thus
promoting cilium disassembly (Pugacheva et al, 2007). Analysis of
the cilium length in cortical neurons proved that both the Aurora A
inhibitor (7 nM, 48 h) and tubacin (1 lM, 48 h) effectively medi-
ated primary cilium elongation in Mecp2 null cells (Fig EV2). By
Western blot, we reported that TC-S 7010, but not tubacin, main-
tains the unaffected levels of cytoplasmic acetylated a-tubulin, con-
firming the more specific action of this inhibitor at the primary
cilium level (Pugacheva et al, 2007; Fig EV3).
Recent studies suggest that proper formation of neuronal
dendrites requires structurally normal primary cilia and a correct
A
D
B C
Figure 5. Tubacin rescues ciliogenesis in MeCP2-deficient cells.
A WT and Mecp2 null MEF cells were starved for 48 h and then treated with the HDAC6 inhibitor tubacin (TUB) (1 lM) for 48 h or with DMSO (VEH) or left untreated
(UT). Cells were fixed and stained for anti-acetylated a-tubulin, and cilia were counted. The graph shows the percentage of ciliated cells out of three independent
experiments (mean  SE, *P < 0.05; **P < 0.01, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA reported a significant genotype effect
(F (1, 10) = 17.94, P < 0.01), a significant tubacin treatment (F (2, 10) = 4.425, P < 0.05), and a significant interaction (F (2, 10) = 7.266, P < 0.05).
B Primary cortical neurons were treated at DIV5 with DMSO (VEH) or tubacin (TUB, 1 lM) for 48 h, or left untreated (UT), fixed at DIV7, and stained with anti-AC3
antibody. The graph shows the percentage of ciliated cells obtained from three independent experiments counting n = 300 UT cells, n = 216 VEH-treated cells, and
n = 267 TUB-treated cells for each genotype (mean  SE, *P < 0.05; **P < 0.01, two-way ANOVA followed by Bonferroni post hoc test). Two-way ANOVA reported a
significant genotype effect (F (1, 15) = 23.42, P < 0.001), a significant treatment effect (F (2, 15) = 11.25, P < 0.01), and a significant interaction (F (2, 15) = 4.853,
P < 0.05).
C MECP2-silenced or control hTERT-RPE-1 cells were starved for 48 h, treated with tubacin (TUB, 1 lM) for 24 h, and then exposed to 200 nM SAG for 24 h in the
presence of tubacin. Cells were stained with anti-Smo and anti-acetylated a-tubulin antibodies, and the percentages of Smo-positive cilia were calculated. The graph
shows the averages of three independent experiments (mean  SE, **P < 0.01, three-way ANOVA followed by Tukey’s post hoc test). Statistical analysis reported a
significant difference between genotype (F (1, 2) = 21.47, P < 0.001), a significant SAG effect (F (2, 2) = 154.5, P < 0.0001), and a significant tubacin effect
(F (1, 2) = 25.18, P < 0.001). In detail, a significant interaction between genotype and SAG treatment (F (2, 2) = 5.413, P < 0.05) and between SAG and tubacin
treatment (F (2, 2) = 6.939, P < 0.01) was reported, demonstrating respectively a difference between CTRL- and MeCP2-depleted cells in response to SAG and a
different SAG effect when cells were treated with tubacin.
D Representative immunostaining of Smo (green) and acetylated a-tubulin (red) in control (CTRL) and silenced (siMeCP2) hTERT-RPE-1 cells, after stimulation with
200 nM SAG in the presence or absence of the HDAC6 inhibitor tubacin (TUB). Scale bar = 50 lm, and 20 lm in the enlarged image.
Source data are available online for this figure.
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localization of signaling proteins into the cilium, thus linking this
organelle to the ability of primary neurons to form correct network
connections (Guadiana et al, 2013). Therefore, by Sholl analysis we
investigated whether tubacin and TC-S 7010 could ameliorate the
typical reduction in dendritic complexity in Mecp2 null neurons
(DIV7) (**P < 0.01, Mann–Whitney test; Bedogni et al, 2016).
Figure 6A, B proves that both molecules significantly increased
dendritic branching, thus recovering defective morphology
(*P < 0.05; **P < 0.01, one-way ANOVA followed by Dunn’s test).
We next analyzed whether HDAC6 inhibition was also effective
in ameliorating the synaptic phenotypes of null neurons (Fig 6C–F).
As expected, the analysis of synaptic puncta density in Mecp2 null
DIV14 cortical neurons reported a significant reduction of both pre-
synaptic Synapsin1/2 and post-synaptic Shank2 puncta (**P < 0.01;
***P < 0.001, Mann–Whitney test; Fig 6D and E). Interestingly,
while TC-S 7010 reverted the defects both at the pre- and the post-
synaptic compartments (***P < 0.001, one-way ANOVA followed by
Dunn’s test), tubacin restored only the density of pre-synaptic
puncta (*P < 0.05, by one-way ANOVA followed by Dunn’s test). As
a measure of functional synapses, we next analyzed the co-localiza-
tion of Synapsin1/2 with Shank2 puncta. As expected, our data high-
lighted a defective co-localization in Mecp2 null neurons compared
A
C
D E F
B
Figure 6.
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to WT cells (***P < 0.001, Mann–Whitney test), which was rescued
only by TC-S 7010 (*P < 0.05, one-way ANOVA followed by Dunn’s
test; Fig 6F).
Tubacin restores defective ciliogenesis in
RTT patients’ fibroblasts
To determine whether the defective ciliogenesis observed in dif-
ferent experimental models would be present also in patients’ cells,
we took advantage of RTT fibroblasts. To this purpose, we used skin
fibroblasts from three RTT female patients characterized by a frame-
shift mutation (705delG) or a premature stop codon (Q224X and
R255X), respectively (Fig 7A). RTT fibroblasts together with 3 inde-
pendent controls were grown to confluence and then starved to
induce growth arrest and cilium formation. Primary cilia were
immunolabeled for acetylated a-tubulin to highlight the axoneme
and for MeCP2 to distinguish cells expressing the WT allele from
those expressing the frameshift mutation or the truncated deriva-
tives. Our data demonstrated that Q244X and R255X fibroblasts
expressed preferentially the mutated allele, while less than 20% of
cells expressed the frameshift mutation 705delG (Fig 7B and C).
This result was confirmed by sequencing the product of an RT–PCR
used to amplify the MECP2 mRNA. Importantly, by counting the
percentage of ciliated cells, we revealed that more than 80% of
control cells presented a primary cilium; on the contrary, the
antenna was present in less than 70% of both fibroblast lines
harboring an MECP2 allele with a nonsense mutation, while the
705delG sample was characterized by a slight but significant reduc-
tion in the percentage of ciliated cells, thus confirming a defect in
ciliogenesis (*P < 0.05; **P < 0.01; ***P < 0.001, one-way ANOVA
followed by Dunnett’s post hoc test; Fig 7D). Further, in all patients’
cells cilium length was affected, indicating primary cilium alteration
as a common tract among the analyzed RTT mutations
(***P < 0.001, two-way ANOVA followed by Bonferroni post hoc
test; Fig 7E). Importantly, tubacin treatment (250 nM, 24 h) caused
a significant cilium elongation in most of the mutant cells, thus
rescuing the structural defect of primary cilium (§P < 0.05, vs.
untreated fibroblasts by two-way ANOVA followed by Bonferroni
post hoc test; Fig 7E).
Discussion
Rett syndrome is a complex neurodevelopmental disorder character-
ized by a plethora of clinical alterations affecting both the central
and the peripheral system, leading to the manifestation of several
symptoms. No treatment is available to combat the primary pathol-
ogy for any of the MECP2-pathies and patients are treated only to
alleviate clinical symptoms. The lack of a full comprehension of the
molecular mechanisms causing MECP2-related pathologies, includ-
ing Rett syndrome, certainly slows down the identification of effec-
tive therapies.
MeCP2 was originally isolated as an epigenetic reader of methy-
lated DNA that represses gene expression mainly through chromatin
compaction (Jones et al, 1998; Nan et al, 2007; Skene et al, 2010).
However, the proposed gene regulatory role has been expanded
beyond gene silencing and chromatin architecture to include tran-
scriptional activation, regulation of mRNA splicing, non-coding RNA
maturation and protein synthesis modulation (Bedogni et al, 2014;
Cheng & Qiu, 2014). While these studies indicate that MeCP2 is a
multifunctional protein, they also highlight that we still do not know
how many functions are associated with MeCP2 and which ones are
relevant to MECP2-related disorders. However, it is commonly
accepted that the majority of clinical symptoms results from the effect
of MeCP2 on gene expression (Bellini et al, 2014). The recently identi-
fied function of MeCP2 at the centrosome diverges from the above-
described roles of the methyl binding protein, since it does not directly
impact on gene transcription (Bergo et al, 2015). Indeed, most func-
tions of the centrosome rotate around its capacity to nucleate and
organize microtubules; in neurons, which represent the cells mostly
involved in Rett syndrome, the centrosome plays several functions. It
is essential for axon formation (Ge et al, 2010) and is generally
considered crucial for cell migration and polarization (Kuijpers &
Hoogenraad, 2011). Furthermore, in these terminally differentiated
cells, the mother centriole of the centrosome migrates toward the cell
surface and converts into a basal body, thereby organizing the assem-
bly of the primary cilium (Stearns, 2001).
Considering our previous data suggesting a centrosomal function
of MeCP2 (Bergo et al, 2015), we found interesting to investigate
whether primary cilium might suffer from structural and/or
◀ Figure 6. HDAC6 inhibition restores neuronal defects associated with the lack of Mecp2HDAC6 inhibition restores neuronal defects associated with the lackof Mecp2.
A Representative images of MAP2-positive WT and Mecp2 null neurons (DIV7). At DIV5, neurons were treated with tubacin (TUB, 1 lM for 48 h) and Aurora A
inhibitor TC-S 7010 (TC-S, 7 nM for 48 h) or left untreated and morphologically analyzed by Sholl analysis plug-in. Scale bar = 20 lm.
B The graph reports the mean  SE of the number of intersections measured 85–145 nm from the soma calculated by Sholl analysis for WT (n = 39 neurons) and
Mecp2 null neurons, when left untreated (n = 57 neurons) or treated with tubacin (n = 53 neurons) or TC-S 7010 (n = 38 neurons). Data from WT and null neurons
were compared by Mann–Whitney test (**P < 0.01); drug effects on null cells were analyzed by one-way ANOVA followed by Dunn’s post hoc test (*P < 0.05;
**P < 0.01).
C Representative images of WT and Mecp2 null neurons (DIV14) immunostained for MAP2 (white), Synapsin1/2 (green), and Shank2 (red). Mecp2 null cells
were treated at DIV12 with tubacin (TUB, 1 lM for 48 h) or Aurora A inhibitor TC-S 7010 (TC-S, 7 nM for 48 h). Scale bar = 15 lm, and 5 lm in the
enlarged image.
D, E The graphs represent the mean  SE of the Synapsin1/2 and the Shank2 puncta density in WT (n = 67 neurons) and Mecp2 null neurons, when untreated (n = 51
neurons) or treated with tubacin (n = 59 neurons) or TC-S 7010 (n = 55 neurons). Neurons derived from at least 6 different biological replicates. Data from WT and
null neurons were compared by Mann–Whitney test (**P < 0.01; ***P < 0.001); drug effects on null cells were analyzed by one-way ANOVA followed by Dunn’s
post hoc test (*P < 0.05; ***P < 0.001).
F The graph depicts the mean  SE of the number of co-localized pre- and post-synaptic puncta (n = 20 neurons deriving from three different biological samples).
Data from WT and null neurons were compared by Mann–Whitney test (***P < 0.001); drug effects on null cells were analyzed by one-way ANOVA followed by
Dunn’s post hoc test (*P < 0.05).
Source data are available online for this figure.
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functional alterations in Mecp2-deficient cells. Indeed, primary cilia
regulate a variety of physiological functions, including metabolism,
cell division and differentiation whose relevance is highlighted by a
long list of heterogeneous disorders, generally called “ciliopathies”
and characterized by defective primary cilia. Notably, minor devia-
tions from the normal range of cilium length characterizing each cell
type can lead to pathogenic phenotypes (Avasthi & Marshall, 2012).
In the mature brain, virtually each neuron contains this cellular
appendage. Although we still lack a clear comprehension of the main
roles of primary cilia in adult neurons, it is generally accepted that
their dysfunction is associated with obesity, cognitive impairment and
developmental disorders (Sterpka & Chen, 2018). On the contrary,
little is known about the functions and consequences of ciliary defi-
ciency in astrocytes (Sterpka & Chen, 2018). Microglia do not display
primary cilia (Sipos et al, 2018) and we still lack evidence of their
presence on mature oligodendrocytes, although they are present on
young oligodendrocyte precursor cells (Falco´n-Urrutia et al, 2015).
Our data demonstrate a structural and functional impairment
of primary cilium in any tested MeCP2-defective cell, ranging
from silenced human cell lines, Mecp2 null neurons, astrocytes,
and Mecp2 knock-out or knock-in MEFs. Furthermore, by exoge-
nously expressing MeCP2 in null neurons, we have proved a
direct link between the expression of the methyl binding protein
and accurate ciliogenesis. Importantly, the presence of primary
cilium defects was confirmed in heterozygous RTT patients’
fibroblasts characterized by premature stop codons or a frameshift
mutation occurring in the TRD and in Mecp2Y120D/y MEFs, harbor-
ing a missense mutation that mainly affects the capacity of the
protein to tightly associate with DNA and chromatin (D’Annessa
et al, 2018; Gandaglia et al, 2018). By inspecting whether the
reduction in the primary cilium length is proportionally related to
a reduction in soma size, we found that Mecp2 null neurons
exhibit the well-known reduction in the soma area that is not
present in RTT patients’ fibroblasts; however, in both cell types
A
B
C D E
Figure 7. RTT patients’ fibroblasts show defective ciliogenesis, which is rescued by tubacin treatment.
A Schematic representation of the MeCP2 protein, with the methyl binding domain (MBD) highlighted in red and the transcriptional repression domain (TRD) in blue.
Patients’ mutations investigated in this study are indicated.
B Representative immunostaining of primary cilia and MeCP2 in cultured human fibroblasts from healthy controls (CTRL, n = 3) and RTT patients. Fibroblasts were
starved for 24 h and then stained for acetylated a-tubulin (green), MeCP2 (red), and DAPI (blue). Scale bar = 50 lm.
C, D Histograms indicate (mean  SE) the percentage of MeCP2-positive cells (C) and the percentage of ciliated cells in control and RTT fibroblasts (D) (*P < 0.05;
**P < 0.01; ***P < 0.001, one-way ANOVA followed by Dunnett’s post hoc test).
E The effect of tubacin (TUB) treatment (250 nM, 24 h) on primary cilium length of controls (CTRL) and RTT fibroblasts is reported. The graph indicates the
mean  SE of the cilium length analyzed in untreated (n = 130 CTRL; n = 73 705delG; n = 57 Q244X; n = 68 R255X) and treated cells (n = 25 CTRL; n = 26
705delG; n = 26 Q244X; n = 49 R255X) (***P < 0.001 vs untreated CTRL, §P < 0.05 vs corresponding mutated untreated fibroblasts by two-way ANOVA followed by
Bonferroni post hoc test). Statistical analysis reported a significant treatment effect (F (1, 429) = 26.56, P < 0.0001) and a significant genotype (F (3, 429) = 42.85,
P < 0.001).
Source data are available online for this figure.
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no correlation exists between primary cilium length and soma
size (Appendix Fig S1).
We hypothesize that the transcriptional functions of MeCP2
contribute to the observed ciliary defects, although an involvement
of its centrosomal functions cannot be excluded. Indeed, we have
recently shown that in the absence of MeCP2, microtubule poly-
merization from centrosomes is impaired (Bergo et al, 2015). In
good accordance, a reduction in microtubule stability associated
with decreased a-tubulin acetylation, caused by increased levels of
HDAC6, was reported (Xu et al, 2014; Gold et al, 2015; Dele´pine
et al, 2016; Landucci et al, 2018). Real-time RT–PCR suggested
that a post-transcriptional mechanism is involved in the observed
HDAC6 upregulation (Dele´pine et al, 2016) and our unpublished
data confirm that Hdac6 mRNA levels are not perturbed in the
Mecp2 null brain. Of note, although the molecular mechanisms
causing this aberrant HDAC6 activity remain unknown, it has
already been reported that miRNA dysregulation can lead to
HDAC6 overexpression (Mansini et al, 2018) and Mecp2 deficiency
affects the transcription of several miRNAs (Ip et al, 2018 and
references therein). These results suggest a possible mechanism
involved in the observed ciliary defect. In fact, it is generally
recognized that by directly affecting microtubule stability, HDAC6
can control ciliary length (De Diego et al, 2014). By demonstrating
that HDAC6 inhibition rescues ciliogenesis in MECP2-mutated cells
with a concomitant amelioration of their typical neuronal dysfunc-
tions, we proved that microtubule instability participates in the
observed phenotypes, thereby offering a possible therapeutic
target. Further, we demonstrated that TC-S 7010, that in post-
mitotic cells preferentially affects HDAC6 activity in the primary
cilium through the inhibition of Aurora A (Pugacheva et al, 2007;
Korobeynikov et al, 2018), is significantly more effective than
tubacin, which inhibits cytoplasmic HDAC6. Altogether these
results support the validity of a pharmacological treatment acting
selectively on the stability of primary cilium and indicate that the
stabilization of primary cilium can lead to an improvement in
neuronal complexity and synaptic alterations, in accordance with
the role of this organelle in neuronal development and synaptic
plasticity (Rhee et al, 2016). Although the exact mechanisms asso-
ciating primary cilium with dendrites are not fully understood,
recent evidence suggests that neuronal dendritogenesis depends on
the formation of structurally and functionally normal cilia (Guadi-
ana et al, 2013). However, although we suggest that the observed
amelioration of the number of synapses and dendrites is associ-
ated with rescued ciliogenesis, we cannot exclude the intervention
of another mechanism independent of cilia formation.
We reinforced our in vitro observations demonstrating defective
ciliogenesis in Mecp2 null and heterozygous mouse brains. Indeed,
we have reported ciliary defects in Mecp2 null cortices (P14) and in
Mecp2 null and heterozygous developing cerebella (P7). The occur-
rence of the defect also in heterozygous brains is particularly rele-
vant to Rett syndrome. Further, most of the cells has reduced cilium
length without showing a bimodal distribution, although almost
40% of them express Mecp2, thereby suggesting the involvement of
a non-cell-autonomous mechanism.
Since the Shh signaling pathway still represents the best-estab-
lished primary cilium-associated pathway, we analyzed whether
MeCP2 dysfunctions might affect it. Our in vitro results proved a
functional impairment of the primary cilium in human and murine
MeCP2-defective samples. Further, our in vivo data indicate that
Mecp2 null cerebella are characterized by reduced levels of Gli1 and
a defective expression of other members of the same pathway, open-
ing up new perspectives for the comprehension of the pathogenic
mechanisms contributing to RTT and their treatment.
Conditional disruption of ciliogenesis in the mouse cortex and
hippocampus impacts on learning and memory and modifies
paired-pulse response of hippocampal neurons (Berbari et al,
2013), and many genes associated with psychiatric disorders affect
ciliogenesis in vitro (Marley & von Zastrow, 2012). Furthermore,
multiple ciliopathies, such as Joubert syndrome and Bardet–Biedl
syndrome, present both neurodevelopmental and cognitive deficits.
As a matter of facts, loss-of-function mutations in ciliary genes
often results in cerebellar hypoplasia, and mice with conditional
mutations disrupting the Shh pathway exhibit defects in cerebellar
foliation and granule cell proliferation (Corrales et al, 2006). Inter-
estingly, previous studies of magnetic resonance imaging (MRI)
have reported a reduction in cerebellar volume both in RTT
patients and in Mecp2 null mouse models (Allemang-Grand et al,
2017; Shiohama et al, 2019). These results, together with the well-
recognized association of cerebellar dysfunctions with autistic-like
behaviors and ataxia (Tsai et al, 2018), prompt a detailed descrip-
tion of the development of Mecp2 null cerebellum and whether
Mecp2 null brains manifest alterations in cortico-cerebellar motor
circuitries. In the future, we will also investigate in mouse models
of RTT the therapeutic potential of rescuing ciliogenesis or the
associated signaling pathways.
To conclude, our data demonstrate for the first time that
MeCP2 influences proper formation and functioning of primary
cilium, which in turn might contribute to the occurrence of central
and metabolic symptoms typical of Rett syndrome. Thus, although
we do not want to define Rett syndrome as a ciliopathy, we
consider important to highlight that it shares several symptoms
with these disorders, such as neurodevelopmental alteration, intel-
lectual disability, autistic features, ataxia, seizures, respiratory
abnormalities, obesity, hypotonia and skeletal bone defects (Hag-
berg et al, 2002; Novarino et al, 2011). We therefore suggest the
importance of future studies testing whether novel pharmacologi-
cal approaches effective for ciliopathies could be re-directed on
Rett syndrome.
Materials and Methods
Drugs
Shh small molecule agonist (SAG) was purchased from Sigma-
Aldrich (SML1314) and dissolved in sterile water. MEFs and hTERT-
RPE-1 cells were treated with SAG (100 nM for MEFs and 200 nM
and 500 nM for hTERT-RPE-1 cells) for 24 h after serum starvation
with low serum medium (0.5% fetal bovine serum). Neurons were
treated with 200 nM and 400 nM SAG for 48 h. Tubacin (SML0065,
Sigma-Aldrich) was dissolved in DMSO. MEFs, neurons, and
hTERT-RPE-1 cells were treated with 1 lM tubacin for 48 h,
whereas fibroblasts were treated with 250 nM tubacin for 24 h in
low serum medium. Aurora A inhibitor I (TC-S 7010, Selleckchem)
was dissolved in DMSO, and a dose of 7 nM was used on neurons
for 48 h.
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Plasmids
To silence MECP2, hTERT-RPE-1 cells were transfected with the
already-described siMeCP2#DH4 (sense, 50-GGAAAGGACUGAA
GACCUGUU-30) or, as corresponding control, the scrambled siRNA
(sense, 50-UAGCGACUAAACACAUCAA-30), both purchased from
Dharmacon (Bergo et al, 2015). Neurons (DIV0) were infected with
the already-described lentiviruses expressing MeCP2iresGFP or
exclusively GFP as control (Stefanelli et al, 2016).
Animals
As lengthily described (Cobolli Gigli et al, 2016), the Mecp2 null
mouse strain, originally purchased from the Jackson Laboratories,
was backcrossed and maintained on a clean CD1 background. These
mice recapitulate the typical phenotype of C57BL/6 mice, with the
advantage of having a larger progeny and minor risk of litter canni-
balization (Cobolli Gigli et al, 2016). Mecp2 null mouse genotype
was determined by PCR protocol on genomic DNA purified from
tails using the following primers: 50-ACCTAGCCTGCCTGTACTTT-30
as forward primer for null allele; 50-GACTGAAGTTACAGATGG
TTGTG-30 as forward primer for wild-type allele; and 50-CCACCCTC
CAGTTTGGTTTA-30 as common reverse primer. Mecp2Y120D/y
mouse genotype was assessed using the following primers: 50-CAG
GGCCTCAGAGACAAGC-30 as common forward primer; 50-GCAGA
TCGGCCAGACTTCC-30 as common reverse primer; and 50-GGGT
TAATTGATATCCAATTGGGATCC-30 as reverse primer for knock-
in allele. For mouse embryonic fibroblasts (MEFs) and neuronal/
astrocytic cultures, wild-type (WT) and Mecp2 null embryos or pups
were generated by mating Mecp2 heterozygous females with WT
male mice. The day of vaginal plug was considered E0.5 and
primary neurons were prepared from E15.5 embryos, while astro-
cytic cultures were prepared from post-natal day 2 (P2) pups. E13.5
embryos were used for MEF preparation. WT and Mecp2 null mice
(P7) derived from three separate litters were used to collect cere-
bella. Mice were rapidly decapitated, brain was removed, cerebel-
lum was isolated and immediately frozen on dry ice and conserved
at 80°C until analysis. P7 and P14 WT, Mecp2 null and heterozy-
gous mice derived from three litters were used for immunostaining
experiments and confocal analysis.
Animals were housed in a temperature- and humidity-controlled
environment in a 12-h light/12-h dark cycle with food and water
ad libitum. All procedures were performed in accordance with the
European Union Communities Council Directive (2010/63/EU) and
Italian laws (D.L.26/2014). Protocols were approved by the Italian
Minister for Scientific Research and by the San Raffaele Scientific
Institutional Animal Care and Use Committee in accordance with
the Italian law.
Cell cultures
Mouse embryonic fibroblasts (MEFs)
Mouse quiescent embryonic fibroblasts were prepared from wild-
type and Mecp2 null E13.5 embryos, as previously described
(Bergo et al, 2015). Harvested embryos were placed in a 10-cm
dish with PBS. Heads were collected for genotyping and the inner
organs were discarded. Each embryo was minced with forceps
and incubated at 37°C for 30 min in 0.25% trypsin/EDTA (Life
Technologies) in PBS. After trypsin removal, the tissue was re-
suspended in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma-Aldrich) with 10% fetal bovine serum (FBS; Gibco) and
antibiotics by gentle trituration with a Pasteur pipette, and the
supernatant was transferred to T25 flasks. MEFs were maintained
in DMEM supplemented with 10% FBS, L-glutamine (Sigma-
Aldrich), and 1% penicillin/streptomycin (P/S; Sigma-Aldrich)
and grown at 37°C with 5% CO2. MEFs were starved for 24 or
48 h with low serum medium (0.5% FBS) and eventually treated
with drugs (SAG and/or tubacin).
Immortalized human retinal pigment epithelial (hTERT-RPE-1)cells
hTERT-RPE-1 (kindly provided by Dr. Storchova, Max-Planck Insti-
tute) cells were maintained in DMEM/F12 (Dulbecco’s modified
Eagle’s medium: 1:1 mixture of DMEM and Ham’s F-12 Nutrient
Mixture; 15 mM HEPES; Sigma-Aldrich); medium was supple-
mented with 10% FBS, L-glutamine and 1% P/S. Cells were grown
at 37°C with 5% CO2. For siRNA transfection, 20 nM siRNA
oligonucleotide targeting MECP2 or control siRNA was transfected
into RPE-1 cells using LipofectamineTM RNAiMAX (Invitrogen).
Silenced cells were processed 96 h post-transfection. After starva-
tion, cells were treated with 1 lM tubacin for 24 h and then exposed
to 200 nM SAG.
Cortical neuronal cultures
Primary cortical neurons were prepared from WT and Mecp2 null
mouse embryos at 15.5 days. Embryos were sacrificed by decapita-
tion and brains were removed under a microscope and immersed in
ice-cold Hank’s Buffered Salt Solution (HBSS; Life Technologies).
Meninges were removed, and cerebral cortex was rapidly dissected
and maintained in cold HBSS. Tissues were incubated with 0.25%
trypsin/EDTA for 7 min at 37°C and the digestion was blocked with
10% FBS in DMEM (Life Technologies). Cortices were then mechan-
ically dissociated by pipetting in Neurobasal medium, containing
10% FBS, 2% B27 (Life Technologies), 1% L-glutamine (Sigma-
Aldrich) and 0.5% P/S (Sigma-Aldrich). For immunofluorescence
experiments, neurons were seeded on coated glass coverslip (1 mg/
ml poly-L-lysine hydrobromide; Sigma-Aldrich) in 24-well dishes at
the density of 50,000 cells/well or at low density (20,000 cells/well)
for morphological analysis.
Cortical astrocyte cultures
Primary astrocyte cultures were prepared from cerebral tissue of
P2 wild-type and Mecp2 null mice. Mice were decapitated and
brain was removed. Meninges were gently stripped off from the
individual cortical lobe and cortices were isolated and immersed
in HBSS containing 10 mM HEPES. Tissues were then immersed
in 0.25% trypsin/EDTA for 30 min at 37°C and then mechanically
dissociated in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies) containing F10 Nutrient (Life Technologies), 10%
FBS and 0.5% P/S. The resulting cells were centrifuged at 400 g
for 7 min, re-suspended in culture medium, and plated in poly-L-
lysine (15 lg/ml)-coated flasks. At DIV4, flasks were shaked at
200 rpm for 8 h at 37°C to eliminate residual microglia, and the
medium was replaced with fresh culture medium. Cells were
incubated in a humidified incubator at 37°C and 5% CO2 until
DIV11 when confluence was reached. Astrocytes were detached
by 0.25% trypsin/EDTA in HBSS and seeded onto glass coverslips
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at a density of 20,000 cells/cm2 for immunofluorescence analysis.
A starvation protocol was applied, by incubating cells with
medium without FBS for 24 h. Glial cultures contained 95%
GFAP+ astrocytes and 5% Iba1+ microglia and no neuron, as
indicated by the lack of MAP2 reactivity.
Human fibroblasts
Human control fibroblasts from healthy individuals (GM00037,
GM00969, and GM01651) and fibroblasts carrying 705delG
(GM07982) and Q244X (GM16548) mutations were provided by
Coriell Institute of Medical Research. Human fibroblasts carrying
R255X mutation (R_FFF2238) were obtained from Telethon
Network of Genetic Biobank. Cells were maintained in DMEM,
containing 10% FBS, 1% L-glutamine, and 1% P/S, and they were
grown at 37°C with 5% CO2. Fibroblasts were starved for 24 h with
low serum medium (0.5% FBS) and then used for immunofluores-
cence and Western blot.
Immunoblot analysis
hTERT-RPE-1, MEFs, and primary cortical neurons were lysed in
ice-cold lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% NP-40, and 1X complete EDTA-free protease inhibitor
cocktail [Roche Diagnostic]) for 30 min on ice and then centrifuged
for 30 min at 10,000 g at 4°C. Cerebella were lysed in ice-cold lysis
buffer for 30 min, sonicated on ice for 10 s at 30 amplitude, and
then clarified by centrifugation for 30 min at 10,000 g (4°C). Protein
concentrations were measured by the Bradford assay (Bio-Rad).
Equal amounts of protein lysates were separated on polyacrylamide
gel for SDS–PAGE and proteins were blotted onto a nitrocellulose
membrane using a semidry transfer apparatus (Trans-blot SD; Bio-
Rad). Membranes were incubated 1 h in blocking solution (Tris-
buffered saline containing 5% nonfat milk and 0.1% Tween-20, pH
7.4) and then incubated overnight (4°C) with the primary antibody
diluted in blocking solution. The following primary antibodies were
used: anti-MeCP2 (M9317; Sigma-Aldrich, 1:1,000), anti-Gli1
(L42B10; Cell Signaling, 1:1,000), anti-acetylated a-tubulin (32-
2700; Invitrogen, 1:2,000), anti-a-tubulin (T5168; Sigma-Aldrich,
1:10,000), and anti-GAPDH (SAB1405848; Sigma-Aldrich, 1:10,000).
After three washes in TBS-T (Tris-buffered saline containing 0.1%
Tween-20, pH 7.4), blots were incubated with HRP-conjugated
secondary antibody (1:10,000 in 5% milk in TBS-T) for 1 h at room
temperature. The immunocomplexes were visualized by using the
ECL substrate (GeneSpin) and Uvitec system. Band density measure-
ments were performed using Uvitec software. Results were normal-
ized to a-tubulin (MEFs, neurons, and cerebella), to GAPDH
(hTERT-RPE-1) or to total protein content (neurons) visualized by a
TGX stain-free method (Bio-Rad).
RNA extraction and quantitative real-time PCR
Total RNA from MEFs, primary neurons and cerebella was extracted
using PureZOL (Bio-Rad) and quantified using a NanoDrop spec-
trophotometer. After having assessed RNA integrity by agarose elec-
trophoresis, RNA was reversely transcribed using the RT2 First
Strand Kit (Qiagen) as instructed by the manufacturer. The resulting
cDNA was used as a template for qRT–PCR with SYBR Green Master
Mix (Applied Biosystems) with designated primers for Gli1: Forward
Primer: GGAAGGGGACATGTCTAGC; Reverse Primer: AATGGCA
CACGAATTCCTTC; CyclinD1: Forward Primer: CCCCAA
CAACTTCCTCTCCT; Reverse Primer: CCAGCCTCTTCCTCCACTT;
and CyclinD2: Forward Primer: GAGTGGGAACTGGTAGTGTTG;
Reverse Primer: CGCACAGAGCGATGAAGGT. Melting curve
showed a single product peak, indicating good product specificity.
HPRT and RPL-13 served as internal standards, and fold change in
gene expression was calculated using the 2(delta Ct) method.
Immunofluorescence
Immunofluorescence on cellular cultures
Cells seeded on glass coverslips were fixed with 4% paraformalde-
hyde in PBS for 30 min at room temperature and then washed
three times with 10 mM PBS. For the analysis of synaptic puncta,
neurons (DIV14) were fixed for 8 min with 4% paraformaldehyde
dissolved in PBS with 10% sucrose. Cells were permeabilized at
4°C in PBS containing 0.1% Triton X-100 for 3 min and blocked
with 10% FBS in PBS for 15 min. Then, cells were incubated with
primary antibody overnight (4°C). Immunofluorescence staining
was done with anti-MeCP2 (M9317, Sigma-Aldrich, 1:100), anti-c-
tubulin (T5326, Sigma-Aldrich, 1:500), anti-acetyl-a-tubulin (lys40,
5335, Cell Signaling, 1:500), anti-Smoothened (ab38686, Abcam,
1:200), anti-adenylate cyclase type 3 (AC3, ab125093, Abcam,
1:1,000), anti-MAP2 (8707, Cell Signaling, 1:1,000), anti-
Synapsin1/2 (ab106006, Synaptic System, 1:500), and anti-Shank2
(ab162211, Synaptic System, 1:300). Cells were then incubated
with Alexa Fluor 488-, Alexa Flour 546-, or Alexa Fluor 647-conju-
gated secondary antibodies (Life Technologies) for 1h and then
washed with PBS. DNA was stained with DAPI solution (1:1,000
in PBS) for 10 min, and slides were mounted with Fluoromount-G
reagent (eBioscience). For the quantitative evaluation of the
percentage of MeCP2-expressing cells, ciliated cell, cilium length,
and ciliary Smo localization, images were acquired from at least
three coverslips for each experimental group with an epi-fluores-
cence microscope by Nikon and analysis was conducted using
ImageJ software. To analyze dendritic complexity, isolated MAP2-
positive neurons at DIV7 were acquired under an epi-fluorescence
microscope by Nikon with a 40× objective and neuronal arboriza-
tion was analyzed by using a Sholl analysis plug-in distributed
with ImageJ software. For the analysis of synaptic puncta,
144.88 × 144.88 lm2 Z-stack images (1,024 × 1,024 pixel resolu-
tion, 8-bit grayscale depth) were acquired at 1× digital zoom using
a 63× oil-immersion objective by laser-scanning confocal micro-
scope (Zeiss LSM 800, Carl Zeiss) with a step size of 0.3 lm. For
each dataset acquisition, parameters (offset background, digital
gain, and laser intensity) were maintained constant among dif-
ferent experiments. By ImageJ software, maximum intensity
projection images were converted to binary images and processed
with a fixed threshold for each channel acquired. The puncta
density was calculated by counting only puncta lying along manu-
ally selected ROIs within 20 lm of 3 primary branches/neuron.
Only puncta with a minimum size of 0.16 lm2 were counted using
Analyze Particles. To assess puncta co-localization of pre- and
post-synaptic markers, the ImageJ Plugin Colocalization highlighter
was run on each Z-stack image acquired. Co-localized puncta were
quantified in manually selected ROIs of the binary mask created
from the maximum intensity projection.
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Immunofluorescence on brain sections
Mice were anesthetized by using a mixture of Rompun/Zoletil and
transcardially perfused with 4% paraformaldehyde in PBS. Brains
were post-fixed overnight at 4°C and slowly dehydrated by using
increasing concentrations of sucrose in PBS at 4°C. Brains were
embedded with Tissue-TEK (O.C.T, Sakura Finetek), frozen in
isopentane, and stored at 20°C. Sectioning was then performed
with a cryostat. Antigen retrieval was applied before immunostain-
ing, and then, sections were permeabilized using 0.3% Triton X-100
in PBS for 30 min and quenched with 0.1 M glycine for 30 min.
Sections were incubated with mouse anti-Arl13b (ab136648, Abcam,
1:300) and/or rabbit anti-ɣ-tubulin (T5326, Sigma-Aldrich, 1:1,000)
primary antibodies, overnight at 4°C, and then with secondary anti-
bodies for 1 h at RT in a solution of 0.2% gelatin, 300 mM NaCl,
and 0.3% Triton X-100 in PBS. DNA was stained in the last wash
using DAPI for 30 min at RT and mounted using ProLong antifade
reagent (Thermo Scientific). Imaging was performed using a Leica
TCS SP5-AOBS 5-channel confocal system (Leica Microsystems)
equipped with a 405-nm diode, an argon ion, and a 561-nm DPSS
laser. Fixed cells were imaged using a PLAPO 40X/1.2 NA oil-
immersion objective. All the images were analyzed by using
Bitplane Imaris software.
Statistical analysis
Data are expressed as mean  SEM and were analyzed using
GraphPad Prism software 7.0. The percentage of ciliated cells
and cilium length in cultured cells and morphological data in
neurons were obtained from cells derived from three separate
experiments. For the pharmacological experiments, cells derived
from the same batch were subdivided among all the experimen-
tal groups. For ex vivo analyses, we used animals derived from
at least three different litters, in order to exclude maternal effect
on the observed phenotypes. Image analyses were performed by
a researcher blind to the genotype and/or treatment. In order to
use the correct statistical test, we first evaluated the normal
distribution of data by applying the D’Agostino–Pearson
normality test. Student’s t-test or Mann–Whitney test was used
for the statistical analysis when WT samples were compared to
Mecp2 mutant samples. One-way ANOVA was used to statisti-
cally compare the effects of tubacin and TC-S 7010 on Mecp2
null neurons. Data from the experiment on neuronal cultures at
different DIVs, from the experiment on infected neurons, and
from Smo-localization experiments and pharmacological experi-
ments were analyzed by two-way ANOVA. Three-way ANOVA
was used to statistically analyze Smo-localization data in h-
TERT-RPE-1 cells following pharmacological treatment. When
there was a significant effect of treatment or genotype, or a
significant interaction between the variables (two-way or three-
way ANOVA), appropriate post hoc test was applied. A P-
value < 0.05 was considered significant.
Expanded View for this article is available online.
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